Description

Repligen’s BioLife Deal Targets $20 Million Of Synergies — Can Cell Therapy Accelerate Growth?

Repligen reported its financial and operational results for the second quarter of 2026, demonstrating continued growth and strategic progress amid a complex bioprocessing market environment. The company achieved $204 million in revenue, reflecting 12% reported growth and 13% organic growth year-over-year, driven primarily by strong recurring revenues across multiple product franchises. Proteins led the growth with approximately 50% expansion, supported by contributions from OEM partnerships and growth factor demand. The Analytics segment also saw robust demand, with a reported increase exceeding 30%, while Chromatography revenue grew in the low double digits. Filtration revenue was stable with slight reported growth but faced challenges related to previously disclosed headwinds, particularly in capital equipment sales, which remained muted but showed promise through a sequential increase in order intake and a healthy order backlog supporting expectations for stronger performance in 2027.